November 3rd, 2019 | 07:37 CET
BAYER, MERCK OR NOVARTIS - WHO BUYS NOXXON PHARMA?
The therapy and cure of serious diseases is a large market with a high willingness to invest. Companies that are active in research and development need experienced teams and partners as well as a lot of liquidity and opportunities to carry out tests. Bayer, Merck and Novartis are well-known global players in the research and treatment of cancer. It is not uncommon for these companies to work with small partners and, if successful, to even acquire them. A transaction may be imminent.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
FURTHER STUDIES ACCORDING TO NEW DATA
The Berlin-based biotech company NOXXON focuses on the treatment of pancreatic and colorectal cancer as well as brain tumors. Based on the published, updated data from the clinical NOX-A12 study in metastatic, microsatellite-stable patients with pancreatic or colorectal cancer in September 2019, NOXXON believes that further clinical studies in these indications are justified.
The development can be described as a successful development. In the next step, the company aims to find industry partners to provide anti-PD1 therapy and financial support to conduct a study.
SIGNIFICANT ADVANCES IN NOX-A12
"The near final data from the NOX-A12 study in combination with immunotherapy in patients with metastatic, microsatellite-stable pancreatic or colorectal cancer and the start of another NOX-A12 study in combination with radiotherapy in the first-line treatment of brain tumor patients are significant advances in the clinical development of NOX-A12 for NOXXON. We are still in discussions with potential partners to enter into agreements to share the financial risks associated with the further development of our cancer therapies," said Aram Mangasarian, Chief Executive Officer of NOXXON.
PHASE 1/2 STUDY HAS STARTED
NOXXON has started the phase 1/2 study with NOX-A12 in combination with radiotherapy. According to the company, patients with inoperable brain tumors (glioblastoma) for whom biomarker analysis confirms that they do not benefit from standard chemotherapy will be treated.
If the data from this study show positive results, the company will discuss the most efficient development path for this indication with the relevant authorities in a Scientific Advice, taking into account orphan drug status in the US and Europe.
ACQUISITION CAN OFFER TIME ADVANTAGE
NOXXON's goal is to identify industry partners for the combination of NOX-A12 with radiotherapy to fund further clinical trials in brain tumors and other indications where radiotherapy is the key component of standard therapy.
NOXXON expects that at least preliminary top-line clinical data from this study will be required to enter into a partnership in this area. The advantage of acquiring NOXXON for a major player is that it will gain a head start in a market worth billions. The coming weeks will be exciting.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
